Buy Tesamorelin UK For Lab Research

Product Description

Tesamorelin Peptide | Buy Tesamorelin UK | Stabilised GHRH Analogue | Research Use Only

Tesamorelin is a synthetic 44-amino acid stabilised analogue of human Growth Hormone-Releasing Hormone (GHRH), and one of the most extensively researched and clinically validated peptides in the GH axis class — studied in laboratory research for its role in pulsatile GH secretion, IGF-1 regulation, visceral adipose biology, and metabolic pathway research. Buy Tesamorelin in the UK from Peptides Lab UK with >99% HPLC-verified purity, batch-specific COA, and fast UK dispatch for laboratory and in vitro research use only.

Distributed by Peptides Lab UK in a high-purity lyophilised format, for laboratory research use only. This compound is handled in controlled settings for in vitro and pre-clinical studies, with no applications in human or veterinary medicine. Each batch undergoes rigorous quality analysis to ensure >99% purity (HPLC verified).

What Is Tesamorelin?

Tesamorelin is a synthetic 44-amino acid polypeptide analogue of growth hormone releasing hormone (GHRH), with the N-terminal portion of the molecule modified to improve its stability and pharmacokinetics in comparison to native GHRH.

The N-terminal amino acid has been amidated with a trans-3-hexenoyl group, which caps the terminus and protects the peptide from cleavage by DPP-4 — resulting in enhanced stability compared with native GHRH in animal models.

What distinguishes Tesamorelin within the GHRH analogue class is its full 44-amino acid sequence — retaining the complete length of endogenous human GHRH — combined with this targeted structural modification for improved proteolytic resistance. Its elimination half-life ranges from 26 to 38 minutes, allowing naturalistic GH pulse patterns without receptor desensitisation.

As a research compound, Tesamorelin UK carries one of the most robust published evidence bases of any synthetic peptide in its class, with peer-reviewed studies spanning neuroendocrinology, adipose biology, metabolic research, and cardiovascular risk modelling.

How Does Tesamorelin Work?

Tesamorelin interacts with the GHRH receptor located on pituitary somatotrophs, initiating intracellular signalling cascades that promote GH synthesis and pulsatile secretion, closely resembling endogenous physiological release patterns.

Unlike direct exogenous GH administration — which bypasses the body’s natural regulatory feedback — Tesamorelin works upstream, engaging the hypothalamic-pituitary axis itself. Because direct administration of recombinant GH bypasses endogenous regulatory feedback loops, research interest has increasingly focused on GHRH analogues as indirect modulators of GH secretion.

GHRH Receptor Activation and cAMP Signalling

In canonical models, GHRH receptor engagement is associated with adenylate cyclase activation and increased intracellular cAMP, supporting downstream phosphorylation events and regulated gene-expression programs relevant to somatotroph and endocrine-axis function.

Pulsatile GH Release and IGF-1 Axis Modulation

Tesamorelin activates GHRH receptors in the pituitary, leading to synthesis and release of growth hormone that acts on multiple cells of the body — including hepatocytes — where it stimulates production of insulin-like growth factor-1 (IGF-1), which mediates many of the downstream effects of growth hormone.

Tesamorelin vs Direct GH Administration

Unlike direct GH administration — which is associated with supraphysiological IGF-1 increases and adverse effects such as fluid retention and insulin resistance — Tesamorelin reduces visceral adipose tissue and triglyceride concentrations without the associated IGF-1-induced increase in insulin resistance, making it a more physiologically nuanced research tool.

What Does Tesamorelin Do in Research?

In laboratory and pre-clinical settings, Tesamorelin has been studied across a broad range of biologically significant pathways. Research has examined its role in:

• Stimulating pulsatile GH release via GHRH receptor agonism in the anterior pituitary
• Modulating IGF-1 axis signalling and downstream anabolic pathway research
• Investigating visceral adipose tissue (VAT) dynamics and lipolysis mechanisms
• Studying lipid metabolism — including triglyceride reduction and lipid partitioning pathways
• Examining hepatic fat content and liver biology in metabolic models
• Cardiovascular risk biomarker research — including carotid intima-media thickness (cIMT) studies
• Neuroendocrine ageing research and GH pulse amplitude modelling
• Comparative GHRH analogue studies alongside Sermorelin and CJC-1295

Tesamorelin and Visceral Adipose Tissue Research

Phase 3 trials demonstrated VAT reductions of 15–18% maintained through 52 weeks, with preservation of subcutaneous adipose tissue and favourable lipid profile changes — findings that have established Tesamorelin as a key research tool in adipose biology.

Tesamorelin and Lipid Metabolism Research

In a pooled analysis of 806 patients across two Phase 3 studies, Tesamorelin produced significant reductions in triglycerides and the cholesterol-to-HDL ratio versus placebo, alongside significant increases in IGF-1 at 26 weeks — with all effects maintained in the continuous treatment group at 52 weeks.

Tesamorelin and Cardiovascular Pathway Research

In abdominally obese research subjects with low peak GH stimulation, 12 months of Tesamorelin significantly decreased carotid intima-media thickness (cIMT), VAT, C-reactive protein, and triglycerides compared to placebo — findings of significant interest in cardiovascular metabolic risk research.

Tesamorelin and GH Axis Biology Research

Tesamorelin is used in experimental models to investigate mechanisms of endogenous GH secretion, downstream IGF-1 signalling, and their associations with metabolic, adipose, and hepatic molecular pathways — with observations interpreted within a mechanistic, non-clinical research framework.

What Do Studies Say About Tesamorelin?

Tesamorelin has one of the most well-documented published research profiles of any synthetic GHRH analogue:

Landmark Phase 3 Clinical Research

A landmark multicenter randomised controlled study published in the New England Journal of Medicine found that Tesamorelin significantly decreased visceral adiposity and concomitant dyslipidaemia without worsening overall glucose tolerance.

Pooled Phase 3 Analysis

A pooled analysis of two multicenter, double-blind, placebo-controlled Phase 3 trials across 806 participants found that Tesamorelin reduced VAT and maintained that reduction for up to 52 weeks, preserved abdominal subcutaneous adipose tissue, improved body image, and improved lipid profiles — without clinically meaningful changes in glucose parameters.

Tesamorelin and GH Pulsatility Research

Comparative studies of Tesamorelin and other GHRH analogues found that both peptides enhance overall GH exposure primarily by prolonging secretory episodes rather than increasing peak GH concentrations — a distinction significant in experimental endocrinology, since sustained supraphysiological GH exposure can introduce confounding variables that pulsatile GHRH analogue models help to avoid.

Tesamorelin and Hepatic Biology Research

Research has examined hepatic lipid handling and transcriptional responses in models where GH and IGF-1 signalling are modulated, using Tesamorelin as a research tool to explore endocrine-metabolic interactions in liver biology.

Key cited studies:

• Falutz J et al. (2010) — Pooled Phase 3 Analysis of Tesamorelin in HIV Lipodystrophy — J Clin Endocrinol Metab 95(9):4291–304. PubMed ID: 20554713
• Falutz J et al. (2007) — Metabolic Effects of Tesamorelin in HIV-Infected Patients — N Engl J Med 357(23):2349–59. DOI: 10.1056/NEJMoa072375
• Makimura H et al. (2012) — Metabolic Effects of Tesamorelin in Obese Subjects with Reduced GH Secretion — J Clin Endocrinol Metab 97(6):2070–80. PubMed ID: 22466344
• Stanley TL et al. (2014) — Tesamorelin Decreases Liver Fat and Hepatic Lipid Metabolism Biomarkers — J Clin Endocrinol Metab 99(3):E449–E458. DOI: 10.1210/jc.2013-3173
• Lo J et al. (2010) — Effects of Tesamorelin on Visceral Adiposity and Metabolic Parameters in HIV-Infected Patients — Clin Infect Dis. PMC3348954

Tesamorelin vs Other GH Axis Research Peptides

Tesamorelin’s full-length GHRH sequence, combined with its targeted N-terminal stabilisation and extensive Phase 3 research dataset, makes it the most clinically well-documented GHRH analogue available for GH axis and adipose biology research.

Quality & Purity Assurance

Every batch of Tesamorelin from Peptides Lab UK is:

• >99% pure — HPLC and mass spectrometry verified
• Supplied with a full Certificate of Analysis (COA) on request
• Lyophilised powder for maximum stability and long shelf life
• Manufactured under strict, controlled laboratory conditions
• Consistent batch-to-batch quality for reproducible research results

Buy Tesamorelin UK — Product Specifications

Tesamorelin Research Applications

Tesamorelin peptide UK is supplied strictly for the following in vitro and pre-clinical research uses:

• GHRH receptor binding and pulsatile GH secretion pathway studies
• GH and IGF-1 axis modulation and downstream signalling research
• Visceral adipose tissue (VAT) dynamics and lipolysis pathway investigations
• Hepatic lipid metabolism and liver biology studies
• Triglyceride, cholesterol, and lipid partitioning metabolic research
• Cardiovascular risk biomarker research (cIMT, CRP, lipid profiles)
• Neuroendocrine ageing and GH pulse amplitude modelling
• Comparative GHRH analogue structure–activity relationship (SAR) studies
• Second-messenger cAMP signalling and transcriptional regulation research

Why Buy Tesamorelin from Peptides Lab UK?

Peptides Lab UK is a trusted UK peptides supplier, providing research-grade compounds verified by independent HPLC testing. When you buy Tesamorelin in the UK from us, you receive:

• >99% purity, HPLC and MS verified, third-party tested
• Full COA documentation per batch
• Fast same-day UK dispatch with tracked delivery
• Competitive pricing with bulk research discounts available
• Trusted by researchers across the UK and Europe

Research Disclaimer All products supplied by Peptides Lab UK are intended strictly for in vitro laboratory research and scientific study use only. They are not intended for human consumption, veterinary use, or any medical or therapeutic application. Tesamorelin is a research compound and is not approved by the MHRA or FDA for any use outside of its specific licensed indication. All research citations on this page relate to pre-clinical studies and peer-reviewed pharmacological research and do not constitute a claim of safety or therapeutic efficacy. Peptides Lab UK accepts no liability for any misuse of research compounds. By purchasing, you confirm that you are a qualified researcher and that the product will be used solely within a controlled laboratory environment in compliance with all applicable UK laws, regulations, and institutional guidelines.